Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)
Clinical trial NCT03492918 · UNKNOWN
Trial details
- NCT number
- NCT03492918
- Sponsor
- Yonsei University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-01
- Primary completion
- 2023-04-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.